The teams’ former medic, who is currently facing a fit-to-practise tribunal, paints a stark picture of the gold-medal factory across 66 pages of eye-opening claims within his written defence, which was disclosed over the weekend.Mr Hancock was today accused...
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky.Selpercatinib is the first drug from...